Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01767779 · ClinicalTrials.gov registry record
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
A clinical trial of Tuberous Sclerosis Complex, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 40
- Enrollment target
- 5
- Study locations
NCT01767779 is a study of Tuberous Sclerosis Complex that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants, below the 152-participant average among 8 other Tuberous Sclerosis Complex trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01767779, a study of Tuberous Sclerosis Complex, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 5
- Study locations
Study Summary
To determine whether EEGs during infancy is a reliable biomarker to identify TSC patients that will develop infantile spasms/epilepsy in the near future and thus are appropriate candidates for an antiepileptogenic drug trial. Since not all patients with TSC develop epilepsy, it would be useful to have a biomarker that could predict those patients destined to have epilepsy and thus identify those TSC patients most appropriate for an antiepileptogenic drug trial. A recent study suggests that treating TSC patients with an abnormal EEG prior to onset of infantile spasms with vigabatrin may improve neurological outcome, but the use of EEG as a reliable biomarker of future epilepsy has not been rigorously validated. In this specific aim, we will test the reliability of EEG in predicting future development of infantile spasms or epilepsy in TSC patients during the first year of life.
Conditions Studied
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- UCLA - Los Angeles
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Cincinnati Children's Hospital - Cincinnati
Texas
- University of Texas in Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-09 |
| Est. Completion | 2018-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01767779
The ClinicalTrials.gov registry entry for NCT01767779 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 152-participant average among 8 other Tuberous Sclerosis Complex trials with a reported enrollment target (74% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tuberous Sclerosis Complex appearing as the primary indexed condition, and to 0 interventions.
NCT01767779 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01767779 about?
NCT01767779 is a clinical study titled "Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC". To determine whether EEGs during infancy is a reliable biomarker to identify TSC patients that will develop infantile spasms/epilepsy in the near future and thus are appropriate candidates for an antiepileptogenic drug trial. Since not all patients with TSC develop epilepsy, it would be useful to ha...
What is the current status of trial NCT01767779?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2012-09. Estimated completion is 2018-12.
What conditions does trial NCT01767779 study?
This clinical trial studies the following conditions: Tuberous Sclerosis Complex.
Who is sponsoring clinical trial NCT01767779?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01767779 being conducted?
This trial has 5 study locations across Alabama, California, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberous Sclerosis Complex
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
RECRUITING
-
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
ACTIVE NOT RECRUITING · Phase 4
-
Feasibility of [11C]Acetate-PET in LAM and TSC
ACTIVE NOT RECRUITING · Phase 1
-
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
ACTIVE NOT RECRUITING · Phase 3
-
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.